Cai Haoye, Huang Honghao, Yang Chenguang, Ren Junli, Wang Jianing, Gao Beibei, Pan Wenjing, Sun Fangyue, Zhou Xinbo, Zeng Tian, Hu Jingyu, Chen Yilin, Zhang Shunkai, Chen Guangyong
Department of Rehabilitation Medicine, The Third Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Department of Neurology, The Third Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Front Neurol. 2021 Jul 12;12:665827. doi: 10.3389/fneur.2021.665827. eCollection 2021.
The eosinophil-to-neutrophil ratio (ENR) was recently reported as a novel inflammatory marker in acute ischemic stroke (AIS). However, few studies reported the predictive value of ENR in AIS patients, especially for those with intravenous thrombolysis. Two hundred sixty-six AIS patients receiving intravenous thrombolysis were retrospectively recruited in this study and followed up for 3 months and 1 year. The Modified Rankin Scale (mRS) and the time of death were recorded. Poor outcome was defined as mRS 3-6. After excluding patients who were lost to follow-up, the remaining 250 patients were included in the 3-month prognosis analysis and the remaining 223 patients were included in the 1-year prognosis analysis. ENR levels in the patients were lower than those in the healthy controls. The optimal cutoff values for the ability of ENR × 10 to predict 3-month poor outcome were 0.74 with 67.8% sensitivity and 77.3% specificity. Patients with ENR × 10 ≥ 0.74 have a lower baseline National Institutes of Health Stroke Scale (NIHSS) score (median: 7 vs. 11, < 0.001). After multivariate adjustment, patients with ENR × 10 ≥ 0.74 were more likely to come to a better 3-month outcome (OR = 0.163; 95% CI, 0.076-0.348, < 0.001). At the 1-year follow-up, the patients with ENR × 10 ≥ 0.74 showed a lower risk of mortality (HR = 0.314; 95% CI, 0.135-0.731; = 0.007). A lower ENR is independently associated with a 3-month poor outcome and a 3-month and 1-year mortality in AIS patients treated with intravenous thrombolysis.
嗜酸性粒细胞与中性粒细胞比值(ENR)最近被报道为急性缺血性卒中(AIS)的一种新型炎症标志物。然而,很少有研究报道ENR在AIS患者中的预测价值,尤其是对于接受静脉溶栓治疗的患者。本研究回顾性纳入了266例接受静脉溶栓治疗的AIS患者,并进行了3个月和1年的随访。记录改良Rankin量表(mRS)和死亡时间。不良结局定义为mRS 3 - 6。在排除失访患者后,其余250例患者纳入3个月预后分析,其余223例患者纳入1年预后分析。患者的ENR水平低于健康对照组。ENR×10预测3个月不良结局的最佳截断值为0.74,敏感性为67.8%,特异性为77.3%。ENR×10≥0.74的患者基线美国国立卫生研究院卒中量表(NIHSS)评分较低(中位数:7对11,<0.001)。经过多变量调整后,ENR×10≥0.74的患者更有可能在3个月时获得较好的结局(OR = 0.163;95%CI,0.076 - 0.348,<0.001)。在1年随访时,ENR×10≥0.74的患者死亡风险较低(HR = 0.314;95%CI,0.135 - 0.731;P = 0.007)。较低的ENR与接受静脉溶栓治疗的AIS患者3个月不良结局以及3个月和1年死亡率独立相关。